Overview
Congenital short bowel syndrome (CSBS), also known as congenital short gut syndrome or congenital short small bowel, is an extremely rare condition present at birth in which the small intestine is significantly shorter than normal. In healthy full-term newborns, the small intestine typically measures approximately 200–300 cm, but in CSBS the intestinal length may be dramatically reduced, sometimes to less than one-third of normal. This shortened bowel results in a markedly reduced absorptive surface area, leading to intestinal failure and severe malabsorption of nutrients, fluids, and electrolytes. The condition primarily affects the gastrointestinal system and can be associated with intestinal malrotation. Affected neonates typically present shortly after birth with chronic diarrhea, vomiting, failure to thrive, dehydration, and progressive malnutrition. The exact cause of CSBS is not fully understood, though it is believed to result from a defect in intestinal development during fetal life. Some cases have been linked to mutations in the CLMP gene (encoding CXADR-like membrane protein), which plays a role in intestinal elongation and morphogenesis during embryonic development. Both autosomal recessive and sporadic forms have been described. CSBS must be distinguished from acquired short bowel syndrome, which results from surgical resection of the intestine due to conditions such as necrotizing enterocolitis or volvulus. Management of congenital short bowel syndrome centers on providing adequate nutrition to support growth and development. Most affected infants require long-term total parenteral nutrition (TPN) to bypass the inadequate intestinal absorption. Enteral feeding is gradually introduced as tolerated to promote intestinal adaptation, a process by which the remaining bowel may increase its absorptive capacity over time. Complications of prolonged TPN, including liver disease (intestinal failure-associated liver disease), catheter-related infections, and metabolic disturbances, represent significant challenges. In severe cases where intestinal adaptation is insufficient and TPN-related complications become life-threatening, small bowel transplantation may be considered. Multidisciplinary care involving pediatric gastroenterologists, surgeons, dietitians, and specialized nutrition teams is essential for optimizing outcomes.
Clinical phenotype terms— hover any for plain English:
Variable
Can be inherited in different ways depending on the underlying gene
Neonatal
Begins at or shortly after birth (first 4 weeks)
FDA & Trial Timeline
4 eventsEclipse Regenesis, Inc. — NA
International University of Health and Welfare — NA
Assiut University — PHASE4
Centre Hospitalier Universitaire de Nice
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
No FDA-approved treatments are currently listed for Congenital short bowel syndrome.
1 clinical trialare actively recruiting — trials can provide access to cutting-edge therapies.
View clinical trials →Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Congenital short bowel syndrome.
Community
No community posts yet. Be the first to share your experience with Congenital short bowel syndrome.
Start the conversation →Latest news about Congenital short bowel syndrome
Disease timeline:
New recruiting trial: A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients With Short Bowel Syndrome
A new clinical trial is recruiting patients for Congenital short bowel syndrome
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Congenital short bowel syndrome
What is Congenital short bowel syndrome?
Congenital short bowel syndrome (CSBS), also known as congenital short gut syndrome or congenital short small bowel, is an extremely rare condition present at birth in which the small intestine is significantly shorter than normal. In healthy full-term newborns, the small intestine typically measures approximately 200–300 cm, but in CSBS the intestinal length may be dramatically reduced, sometimes to less than one-third of normal. This shortened bowel results in a markedly reduced absorptive surface area, leading to intestinal failure and severe malabsorption of nutrients, fluids, and electrol
At what age does Congenital short bowel syndrome typically begin?
Typical onset of Congenital short bowel syndrome is neonatal. Age of onset can vary across affected individuals.
Are there clinical trials for Congenital short bowel syndrome?
Yes — 1 recruiting clinical trial is currently listed for Congenital short bowel syndrome on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat Congenital short bowel syndrome?
19 specialists and care centers treating Congenital short bowel syndrome are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.